Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.

AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...

Belite Bio has concluded the final participant visit in its Phase III DRAGON study, which is focused on assessing the ...

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...

The main concerns about tariffs that businesses have are higher input costs and uncertainty in long-term planning.

Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo, designed to increase study ...

Amidst significant shifts in the pharmaceutical industry, the number of clinical trials has surged over the first half of ...

AMT-103 will likely not be available for all patients with HD. Credit: bangoland/Shutterstock.com. On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies ...

Johnson & Johnson said the combination was investigated in 49 patients with newly diagnosed multiple myeloma. Image credit: PixelBiss / Shutterstock.com Johnson & Johnson’s (J&J’s) multiple myeloma ...

Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.

In the head-to-head trial, Lilly’s oral drug emerged on top, outperforming Novo Nordisk’s semaglutide.